Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(10 years from now) | |
US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
US11708333 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) | |
US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
NCE-1 date: 03 December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL